PHATHOM PHARMACEUTICALS INC (PHAT) competitors & alternatives
Health Care · NASDAQ
PHATHOM PHARMACEUTICALS INC (PHAT)'s top competitors and alternatives — its most similar public companies — include ASTRAZENECA PLC (AZN), Pfizer (PFE), MIRUM PHARMACEUTICALS INC (MIRM), Ultragenyx (RARE), SAGIMET BIOSCIENCES INC SERIES A (SGMT), LUCID DIAGNOSTICS INC (LUCD), ESPERION THERAPEUTICS INC (ESPR), ARDELYX INC (ARDX), ETON PHARMACEUTCIALS INC (ETON), SYNDAX PHARMACEUTICALS INC (SNDX), Insmed (INSM) and IRONWOOD PHARMA INC CLASS A (IRWD). These are PHATHOM PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PHAT competitors & alternatives
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
SAGIMET BIOSCIENCES INC SERIES ASGMTHealth Care
Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other…
$7.05 (as of 2026-07-22) · market cap $431M
-
LUCID DIAGNOSTICS INCLUCDHealth Care
Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at…
$0.94 (as of 2026-07-22) · market cap $192M
-
ESPERION THERAPEUTICS INCESPRHealth Care
Esperion commercializes NEXLETOL and NEXLIZET, first-in-class non-statin ACLY inhibitors proven to reduce cardiovascular risk in statin-intolerant or…
$3.18 (as of 2026-07-13) · market cap $819M
-
ARDELYX INCARDXHealth Care
Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3…
$5.08 (as of 2026-07-22) · market cap $1.3B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
-
SYNDAX PHARMACEUTICALS INCSNDXHealth Care
Syndax Pharmaceuticals is a clinical-stage and commercial-stage biotechnology company developing a pipeline of targeted cancer therapies, including approved…
$22.05 (as of 2026-07-22) · market cap $2.0B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
IRONWOOD PHARMA INC CLASS AIRWDHealth Care
Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline…
$3.88 (as of 2026-07-22) · market cap $637M
Not quite? Describe exactly what you want →
Peers are PHATHOM PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PHATHOM PHARMACEUTICALS INC (PHAT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.